academic article

1560PDMajor determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey.  Annals of Oncology.  29. 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries..  Journal of Clinical Oncology.  36. 2018
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017.  European Journal of Cancer.  77. 2017
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016.  Journal of Translational Medicine.  15. 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.  The Lancet Oncology.  18. 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.  JAMA Oncology.  3. 2017
Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.  Journal of Dermatological Treatment.  28. 2017
1389O_PR More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs.  Annals of Oncology.  27. 2016
LBA2_PR melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial.  Annals of Oncology.  27. 2016
Melanoma and immunotherapy bridge 2015.  Journal of Translational Medicine.  14. 2016
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.  The Lancet Oncology.  16. 2015
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial..  Journal of Clinical Oncology.  32. 2014
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial..  Journal of Clinical Oncology.  32. 2014